Medicare Enrolled
Dr. Saritha Dodla, M.D.
Cardiovascular Disease · Fort Worth, TX
Practice pattern: Cardiac & Remote— Practice combining cardiac and remote services
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Dodla from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Dodla? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Dodla
Dr. Saritha Dodla is a cardiovascular disease in Fort Worth, TX, with 19 years in practice. Based on federal Medicare data, Dr. Dodla performed 5,561 Medicare services across 3,775 unique beneficiaries.
Between the years covered by Open Payments, Dr. Dodla received a total of $2,499 from 26 pharmaceutical and/or device companies across 129 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Dodla is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 13% volume in TX$ $2,499 industry payments
Medicare Practice Summary
Medicare Utilization ↗5,561
Medicare services
Top 13% in TX for cardiovascular disease
3,775
Unique beneficiaries
$81
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~293 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (20-29 min) | 793 | $60 | $140 |
| Office visit, established patient (30-39 min) | 758 | $88 | $200 |
| Echocardiogram, transthoracic | 639 | $135 | $698 |
| Remote patient monitoring management, 20 min/month | 266 | $38 | $150 |
| Electrocardiogram (EKG), 12-lead | 265 | $10 | $70 |
| Remote patient monitoring device, 30 days | 229 | $39 | $180 |
| Remote pacemaker/defibrillator monitoring, 90 days | 195 | $18 | $71 |
| Regadenoson injection (Lexiscan) for heart stress test | 184 | $43 | $150 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 183 | $31 | $120 |
| New patient office visit (45-59 min) | 165 | $115 | $320 |
| Remote pacemaker monitoring, 90 days | 159 | $23 | $94 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 153 | $10 | $100 |
| Ultrasound of both sides of head and neck blood flow | 103 | $143 | $785 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 89 | $63 | $272 |
| Nuclear medicine study of heart muscle blood flow by pet | 88 | $21 | $90 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 83 | $357 | $488 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 81 | $339 | $1,200 |
| EKG interpretation and report | 77 | $6 | $20 |
| Office visit, established patient, complex (40-54 min) | 77 | $123 | $280 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 76 | $21 | $74 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 75 | $30 | $110 |
| Programming of dual lead pacemaker system | 72 | $26 | $108 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 68 | $20 | $50 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 65 | $17 | $100 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) | 65 | $21 | $140 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 62 | $650 | $1,300 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 58 | $131 | $624 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 57 | $53 | $305 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 42 | $20 | $74 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 41 | $28 | $186 |
| Ultrasound of heart, follow-up | 36 | $63 | $321 |
| Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | 34 | $132 | $763 |
| Evaluation of cardiac rhythm monitor system | 23 | $13 | $59 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 20 | $50 | $400 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 20 | $15 | $48 |
| Initial hospital admission, high complexity | 20 | $136 | $382 |
| Destruction of first incompetent vein of arm or leg using radiofrequency and imaging guidance | 17 | $724 | $5,437 |
| Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 16 | $203 | $750 |
| Ultrasound of leg arteries or artery grafts | 16 | $160 | $827 |
| New patient office visit (30-44 min) | 16 | $76 | $200 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring | 15 | $6 | $75 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 13 | $10 | $37 |
| Electrocardiogram (ecg) 2-day continuous | 12 | $8 | $90 |
| Telephone medical discussion with physician, 5-10 minutes | 12 | $27 | $136 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $44 | $155 |
| Cardiac catheterization | 11 | $223 | $1,000 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
20.7% high complexity
17.5% medium
61.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,499
Total received (2018-2024)
Avg $357/year across 7 years
Bottom 35% in TX for cardiovascular disease
26
Companies
129
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,419 (96.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$79 (3.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$514
2023$443
2022$445
2021$285
2020$142
2019$330
2018$341
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Abbott Laboratories
$644
Merck Sharp & Dohme LLC
$271
PFIZER INC.
$220
Cleerly, Inc.
$195
AstraZeneca Pharmaceuticals LP
$155
Gilead Sciences, Inc.
$121
Boston Scientific Corporation
$89
Inspire Medical Systems, Inc.
$82
Janssen Pharmaceuticals, Inc
$75
Kiniksa Pharmaceuticals, Ltd.
$66
Tactile Systems Technology Inc
$65
Novartis Pharmaceuticals Corporation
$61
SANOFI-AVENTIS U.S. LLC
$61
E.R. Squibb & Sons, L.L.C.
$59
Medtronic Vascular, Inc.
$58
Medtronic, Inc.
$44
Boehringer Ingelheim Pharmaceuticals, Inc.
$42
SCPHARMACEUTICALS INC.
$41
CARDIVA MEDICAL, INC.
$36
Philips North America LLC
$26
Kiniksa Pharmaceuticals International, plc
$24
Kowa Pharmaceuticals America, Inc.
$13
Cardinal Health 200, LLC
$13
Merck Sharp & Dohme Corporation
$13
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$13
Amgen Inc.
$11
Top 3 companies account for 45.4% of total payments
Associated products mentioned in payments ›
(CK4) MCOT · Arcalyst · Assurity Pacemaker · BRILINTA · BodyGuardian · CHANTIX · Cleerly Ischemia · Confirm Rx · Corlanor · ELIQUIS · ENSITE PRECISION · ENTRESTO · FARXIGA · FFRANGIO · FUROSCIX · Flexitouch Plus · INSPIRE · JARDIANCE · JOT DX · LEQVIO · LifeVest · Livalo · MULTAQ · Mozec NC PTCA Balloon · REVEAL LINQ · Resolute · VERQUVO · VYNDAQEL · Vascular Closure Device · WATCHMAN Access System · XARELTO · Xience Sierra Coronary Stent
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $45 per 100 Medicare services performed
Geographic Context
Cardiovascular Diseases within 10 mi
109
Per 100K population
5.1
County median income
$81,905
Nearest hospital
TEXAS HEALTH HARRIS METHODIST HOSPITAL ALLIANCE
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Dodla is a cardiac & remote specialist, with above-average Medicare volume (top 13% in TX), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Dodla experienced with office visit, established patient (20-29 min)?
Based on Medicare claims data, Dr. Dodla performed 793 office visit, established patient (20-29 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Dodla receive payments from pharmaceutical companies?
Yes. Dr. Dodla received a total of $2,499 from 26 companies across 129 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Dodla's costs compare to other cardiovascular diseases in Fort Worth?
Dr. Dodla's average Medicare payment per service is $81. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Dodla) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Cardiovascular Diseases in Fort Worth
Browse cardiovascular diseases in Fort Worth ranked by procedure volume and transparency data.
Highest volume
Top Cardiovascular Diseases in TX
Cardiovascular Diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Cardiovascular Diseases in TX
Which TX cardiovascular diseases receive the most from drug and device companies.
By company
Abbott Laboratories Payments to Doctors
See all physicians who received payments from Abbott Laboratories.
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology